Justification of Risk-Benefit

Justification of Risk-Benefit refers to the formal evaluation demonstrating that the potential therapeutic benefits of a drug or trial outweigh known and potential risks. This assessment supports ethical approval, regulatory decision-making, and clinical development progression. Risk-benefit evaluation evolves over time as new safety and efficacy data emerge from preclinical studies, early clinical trials, and ultimately pivotal programmes.

The biopharmaceutical industry continuously updates risk-benefit assessments during development, incorporating preclinical findings, early clinical safety signals, and efficacy outcomes. Regulatory submissions include risk management plans, safety monitoring strategies, and justification for continued development in defined populations. Ethics committees evaluate risk-benefit for trial approval, particularly in vulnerable groups or when experimental therapies carry significant uncertainties. Post-marketing surveillance further refines risk-benefit understanding, informing label updates, restrictions, or risk minimisation measures. As therapies become more complex and target increasingly specific patient populations, robust and transparent risk-benefit justification remains central to responsible development and ongoing patient protection.